Health

South Korean lab automation specialist Curiosis showcased its AI-powered self-driving laboratory technology at the 2026 World Bio Summit and held partnership talks with global pharmaceutical companies and overseas research institutions.

A predictive model has been developed to differentiate skin cancer and precancerous lesions using biopsy results and skin condition analysis.

South Korea and the World Health Organization have issued a joint declaration calling for responsible AI-driven healthcare innovation, stronger global cooperation and equitable access to its benefits regardless of a country’s wealth or income levels.

Celltrion is strengthening its European market presence through acquisitions, pharmacy-channel expansion and country-specific sales strategies, aiming to sustain growth in the fourth quarter following record quarterly results and rising sales of higher-margin products.

JNP Medi has introduced a beta version of Maven Safety AI Import, a new feature that uses AI to extract data from adverse event reports and automatically populate fields according to the ICH E2B(R3) electronic reporting standard to streamline pharmacovigilance workflows.

Samsung Bioepis announced that its investigational Nectin-4-targeting antibody-drug conjugate SBE303 has received U.S. FDA Fast Track designation for patients with locally advanced or metastatic urothelial cancer previously treated with a Nectin-4-targeted therapy.

Surgical AI robotics company Rosota has reported preclinical research demonstrating that AI trained on surgeons’ laparoscopic procedures can execute corresponding movements with a real robot, with testing in animals and postoperative survival monitoring.

Medyssey secures three FDA 510(k) certifications this year, enhancing its strategy in the U.S. spinal implant market.

Celltrion is accelerating global expansion with high market share in key Asian and Latin American markets.

The government, National Assembly, and biotech firms gather to explore global market strategies for Korea's bio-healthcare industry.

Huons presented non-clinical research results of selective TG2 inhibitor HUC1A-626 at UEG Week 2026 in Barcelona.

Daewoong Pharmaceutical held its first Nabota Master Class in Latin America in Buenos Aires, bringing together about 200 medical professionals from six countries to share clinical expertise and aesthetic treatment techniques using its botulinum toxin product.

Lunit will present five research abstracts using its AI biomarker platform Lunit SCOPE at ESMO 2026, including studies on HER2-low breast cancer, non-small cell lung cancer and pancreatic cancer.

Samsung Bioepis has signed a local partnership agreement to exclusively supply its eculizumab biosimilar SB12 to Brazil’s Ministry of Health for 10 years, expanding its presence in Latin America’s largest pharmaceutical market.